Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panitumumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    163 result(s) found for: Panitumumab. Displaying page 5 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-011882-10 Sponsor Protocol Number: GETUG-AFU 19/0901 Start Date*: 2010-02-26
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mu...
    Medical condition: Advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001490-33 Sponsor Protocol Number: UC-0110/1608 Start Date*: 2016-10-25
    Sponsor Name:UNICANCER
    Full Title: Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.
    Medical condition: RAS and B-RAF wild-type metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015237-76 Sponsor Protocol Number: LUC 09-002 Start Date*: 2010-04-26
    Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc
    Full Title: An open label multicentric phase II study of Panitumumab (Vectibix®) in cutaneous squamous cell carcinoma (SCC)
    Medical condition: Cutaneous Squamous Cell Carcinoma (SCC)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041823 Squamous cell carcinoma LLT
    12.1 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019595-79 Sponsor Protocol Number: UMCNONCO200905 Start Date*: 2010-10-15
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic)
    Medical condition: histology proven irresectable squamous cell or adenocarcinoma of the oesophagus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055476 Esophageal squamous cell carcinoma LLT
    12.1 10055458 Esophageal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017731-17 Sponsor Protocol Number: AIO-KRK-0109 Start Date*: 2011-02-01
    Sponsor Name:AIO-Studien-gGmbh
    Full Title: An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type
    Medical condition: non-resectable metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000347-60 Sponsor Protocol Number: TTD-18-01 Start Date*: 2018-08-08
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + pa...
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002222-37 Sponsor Protocol Number: 1626 Start Date*: 2016-09-07
    Sponsor Name:Herlev og Gentofte Hospital
    Full Title: A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.
    Medical condition: Patient with metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10010028 Colorectal cancer Duke's D LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017871-13 Sponsor Protocol Number: ME GD 203 Start Date*: 2010-10-05
    Sponsor Name:New Medical Enzymes AG
    Full Title: A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-ta...
    Medical condition: Adult patients with unresectable or metastatic colorectal cancer showing progression of disease on at least one fluoropyrimidine derivative, oxaliplatin, irinotecan and EGFR-antibodies (cetuximab o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019238-29 Sponsor Protocol Number: 40091 Start Date*: 2013-06-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from w...
    Medical condition: Resectable liver metastases from wild type KRAS and NRAS colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024700 Liver metastases LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) GB (Completed) DE (Prematurely Ended) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012453-38 Sponsor Protocol Number: Start Date*: 2009-09-14
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb
    Medical condition: primary cancer of the uterine cervix stage Ib-IIIb
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015119-42 Sponsor Protocol Number: GMIHO-007/2008_AG48 Start Date*: 2010-05-12
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) ve...
    Medical condition: Locally advanced/metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046721 Urothelial carcinoma bladder stage III LLT
    12.1 10046722 Urothelial carcinoma bladder stage IV LLT
    12.1 10046724 Urothelial carcinoma ureter local LLT
    12.1 10046725 Urothelial carcinoma ureter metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004231-72 Sponsor Protocol Number: IBICCR2018-01 Start Date*: 2019-06-27
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
    Full Title: Randomized study of the detection of RAS / BRAF mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer RAS / BRAF WT a...
    Medical condition: Median of the progression-free survival of patients with mCRC who maintains the treatment in conventional 1st line, QT + anti-EFGR, versus patients who withdraw anti-EGFR therapy after detection of...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017428-17 Sponsor Protocol Number: 20091105 Start Date*: 2010-05-31
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO
    Full Title: A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma
    Medical condition: advanced intrahepatic colangiocarcinoma and extrahepatic biliary adenocarcinoma including gallbladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008594 LLT
    9.1 10025943 LLT
    9.1 10061239 LLT
    9.1 10022789 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013756-79 Sponsor Protocol Number: VECTOX Start Date*: 2010-09-28
    Sponsor Name:Anticancer Informing "Me Gnosi Nika"
    Full Title: VECTIBIX PLUS OXALIPLATIN-BASED ADJUVANT TREATMENT OF RECTAL CANCER
    Medical condition: Rectal cancer stage 2-3 includes neoadjuvant chemo radiation, followed by resection, followed by adjuvant chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010033 Colorectal cancer stage II LLT
    12.1 10010034 Colorectal cancer stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018993-20 Sponsor Protocol Number: P-FLOT Start Date*: 2011-01-26
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the g...
    Medical condition: Adenocarcinoma of the stomach or the gastroesophageal junction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017768 Gastric cancer stage IV without metastases LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017767 Gastric cancer stage IV with metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001987-55 Sponsor Protocol Number: 87163246 Start Date*: 2007-09-27
    Sponsor Name:University Of Birmingham
    Full Title: Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer: A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody impr...
    Medical condition: Patients with high-risk, operable colon cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009956 Colon cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001928-19 Sponsor Protocol Number: C12-2 Start Date*: 2014-01-23
    Sponsor Name:GERCOR
    Full Title: Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study.
    Medical condition: Unresectable Wild-Type KRAS Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000456-26 Sponsor Protocol Number: Tumorspheres_Colrec Start Date*: 2017-07-10
    Sponsor Name:Vejle Hospital
    Full Title: Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002533-14 Sponsor Protocol Number: REVERT Start Date*: 2021-02-15
    Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: REVERT – taRgeted thErapy for adVanced colorEctal canceR paTients.
    Medical condition: unresectable metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005428-41 Sponsor Protocol Number: 02044190615-01 Start Date*: 2014-12-01
    Sponsor Name:Department of experimental and clincial medicine "F. Magrassi"
    Full Title: Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer
    Medical condition: The present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirim...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 12:43:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA